2022.04.06, Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelera
READ MORE 2022-07-06News List
Vijoice is the first FDA-approved PRS treatment
Systemic lupus erythematosus (SLE) oral new drug! BMS Novel Oral TYK2 Inhibitor deucravicitinib
Bristol-Myers Squibb (BMS) recently announced positive results from the Phase 2 PAISLEY study (NCT03
READ MORE 2022-06-13
Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadelumab)
Takeda announced the Phase 3 SHP643 to evaluate the safety and pharmacokinetics of Takhzyro (lanadel
READ MORE 2022-05-13
Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension trial of the novel oral TYK2 inhibitor deucravacitinib
Recently, Bristol-Myers Squibb (BMS) presented 2-year data from the POETYK PSO long-term extension t
READ MORE 2022-05-12
AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved
READ MORE 2022-03-11
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (
READ MORE 2022-02-10
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare announced that the US Food and Drug Administration (FDA) approvedApretude, the first
READ MORE 2021-12-22
Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud
READ MORE 2021-11-01
Hengrui announces new drug SHR7280
On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treat
READ MORE 2021-10-15
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S.
READ MORE 2021-09-07